Contineum Therapeutics, Inc. Class A Common Stock
Veridion Score
Composite trend over time
Why is CTNM moving today?
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CTNM.
CTNM insider activity
Contineum Therapeutics, Inc. Class A Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CTNM.
CTNM contract awards, year to date.
Public federal awards linked to this ticker.
CTNM lobbying filings, year to date.
Registered lobbying filings matched to Contineum Therapeutics, Inc. Class A Common Stock.